Free Trial

Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Here's What Happened

Telix Pharmaceuticals logo with Medical background

Key Points

  • Telix Pharmaceuticals experienced a significant trading volume increase of 55%, with about 63,048 shares traded recently, compared to 40,576 shares the previous session.
  • Analysts have a generally positive outlook on TLX, with an average Buy rating and a consensus target price of $22.33.
  • Several institutional investors have recently acquired new stakes in Telix Pharmaceuticals, indicating growing interest and confidence in the company's prospects.
  • Want stock alerts on Telix Pharmaceuticals? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw an uptick in trading volume on Tuesday . 63,048 shares traded hands during mid-day trading, an increase of 55% from the previous session's volume of 40,576 shares.The stock last traded at $11.48 and had previously closed at $11.90.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TLX. HC Wainwright initiated coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They set a "buy" rating and a $23.00 price objective for the company. Wedbush reissued an "outperform" rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th. Finally, William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Telix Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $22.33.

Get Our Latest Research Report on TLX

Telix Pharmaceuticals Stock Up 3.2%

The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66. The company's fifty day moving average price is $14.47 and its 200 day moving average price is $16.27.

Institutional Trading of Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. IHT Wealth Management LLC acquired a new position in Telix Pharmaceuticals during the 2nd quarter valued at approximately $213,000. Jane Street Group LLC bought a new stake in Telix Pharmaceuticals in the second quarter valued at $564,000. Russell Investments Group Ltd. bought a new stake in Telix Pharmaceuticals in the second quarter valued at $975,000. Pier Capital LLC acquired a new position in shares of Telix Pharmaceuticals during the second quarter valued at $3,037,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of Telix Pharmaceuticals during the second quarter worth about $297,000.

About Telix Pharmaceuticals

(Get Free Report)

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

Further Reading

Should You Invest $1,000 in Telix Pharmaceuticals Right Now?

Before you consider Telix Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.

While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines